HLS Therapeutics Inc (TSE:HLS) has released an update.
At the recent virtual Annual Meeting of HLS Therapeutics Inc., shareholders cast their votes, resulting in the decisive re-election of the company’s board members, with most directors receiving over 90% approval. Additionally, the firm reaffirmed its partnership with Ernst & Young LLP as auditors, receiving unanimous shareholder support. HLS Therapeutics continues to focus on acquiring and commercializing branded pharmaceuticals in North America, particularly in the central nervous system and cardiovascular areas.
For further insights into TSE:HLS stock, check out TipRanks’ Stock Analysis page.
